Publications Repository - Helmholtz-Zentrum Dresden-Rossendorf

2 Publications
Synthesis and Functionalization of Radium-doped Barium Sulfate Nanoparticles
Reissig, F.; Bauer, D.; Pietzsch, H.-J.; Steinbach, J.; Mamat, C.ORC
The radionuclides radium-223 and radium-224 are two alpha-emitting radionuclides with suitable properties for the TAT. To this date, radium-223 in form of [223Ra]radium chloride (Xofigo) is the only EMA and FDA approved alpha-emitting radiopharmaceutical. Due to its calcimimetic behavior, the radium ion is a bone-seeking therapeutic. To extend the radiopharmaceutical potential of both radionuclides, novel carrier systems have to be developed. Therefore, it is appropriate to investigate different kinds of nanoparticles for their ability to transport radium. Especially, a barium sulfate matrix seems to be sufficient since the principle of co-precipitating the sulfates of radium and barium allows an easy and fast synthesis of radium-doped nanoparticles. Beyond the incorporation of alpha-emitting radionuclides like radium-223 and radium-224, the homologue radionuclide barium-131 can be incorporated as well. Barium 131 decays by electron capture and provides suitable properties for diagnostic applications in nuclear medicine. Radium-223/-224 and barium-131 form a matched pair for new theragnostic approaches. In our research group, we are developing simple methods for the synthesis of small radiolabeled radium/barium sulfate nanoparticles. Furthermore, we are investigating suitable surface functionalizations to attach biological targeting moieties.
Keywords: Bariumsulfat, Radium-224, Nanopartikel
  • Poster
    11th International Symposium on Targeted-Alpha-Therapy, 01.-06.04.2019, Ottawa, Kanada
  • Open Access LogoAbstract in refereed journal
    Journal of Medical Imaging and Radiation Sciences 50(2019)1, S38-S38
    DOI: 10.1016/j.jmir.2019.03.117

Publ.-Id: 29009 - Permalink